First experience of durable cytoreduction in chronic lymphoid leukemia with 177Lu-DOTATATE
- 44 Downloads
This is the first described case of effective and durable cytoreduction after PRRT with 177Lu-DOTATATE in a 75-year-old female, with B cell chronic lymphoid leukemia, and well-differentiated metastatic neuroendocrine tumor.
KeywordsPET/CT 117Lu-DOTATATE Chronic lymphoid leukemia Neuroendocrine tumor PRRT
Compliance with ethical standards
Conflict of interest
All the authors declared that they have no conflict of interest.
- 2.Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:2416–23.CrossRefGoogle Scholar
- 6.Sabet A, Ezziddin K, Pape U-F, Ahmadzadehfar H, Mayer K, Pöppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med Off Publ Soc Nucl Med. 2013;54:1857–61.Google Scholar